UAE – The Abu Dhabi Health Services Company (SEHA), a subsidiary of PureHealth, has partnered with French pharmaceutical company Sanofi to expand diagnostic capabilities for rare diseases.
This development follows the identification, development, and possible solutions and treatments for rare diseases as a focus area in which PureHealth’s capabilities can help SEHA.
Under this collaborative agreement, SEHA and Sanofi will leverage their respective expertise to enhance diagnostic performance and accuracy in the field of rare diseases.
The overall partnership has a particular focus on expediting the screening process for lysosomal storage disorders (LSDs) and reducing the average diagnostic journey for rare disease patients.
It is designed to cater to persons with lysosomal storage disorders including Gaucher disease, Acid Sphingomyelinase Deficiency (ASMD) disease B and A/B, Pompe disease, Fabry disease, and Mucopolysaccharidosis diseases.
In his address, Saeed Jaber Al Kuwaiti, Group Chief Executive Officer of SEHA said: “We are very excited to join hands with Sanofi in our endeavor to empower the patient community by enabling effective diagnosis and sustainable access to treatment and bring rare disease patients into the mainstream of the public health system.”
Working in collaboration with SEHA, Sanofi will leverage its extensive expertise in disease pathways to expedite the generation and application of clinical knowledge for the accurate diagnosis of patients with LSDs.
Sanofi seeks to remove the barriers and delays in the diagnosis of LSD patients, improve their access to effective treatment, and ultimately, transform the rare disease diagnostics landscape in the UAE.
To this end, Sanofi will offer a comprehensive suite of sponsored services to enhance patient access to an early and precise diagnosis including covering the expenses associated with laboratory testing.
The French drugmaker will assume the expenses associated with the packaging, storage, and shipment of samples to accredited send-out laboratories.
Sanofi will also provide training programs to SEHA’s healthcare professionals (HCPs) on sample collection procedures and best practices.
These initiatives come as part of the company’s efforts to provide its innovations to rare disease patients in the Greater Gulf region and to offer patient support through its humanitarian program.
Commenting on the deal with SEHA, MCO Lead, and General Manager for Specialty Care at Sanofi Greater Gulf, Scheuer Jean-Paul, said: “Creating value-generating partnerships is essential to accelerating healthcare innovation and unlocking new possibilities for patients.”
Through this strategic alliance with Sanofi, SEHA is expected to integrate genetic testing for rare diseases into their electronic systems, facilitating differential diagnostics panels and early detection of rare conditions.
The strategic alliance has the potential to fundamentally revolutionize diagnostic performance and expedite the screening process for lysosomal storage disorders, and improve health outcomes.
It will help in empowering patients with rare diseases and stemming the rising number of patients leaving the country to access cutting-edge therapies for the treatment of numerous rare diseases overseas.
As a result, it will significantly contribute to the UAE’s efforts to alleviate the economic and clinical burden associated with rare diseases and to provide effective solutions for individuals living with rare genetic disorders.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
